Trial reportJACC. Cardiovascular imaging2020
Ticagrelor to Reduce Myocardial Injury in Patients With High-Risk Coronary Artery Plaque.
Trial report in JACC. Cardiovascular imaging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02110303 (Dual Antiplatelet Therapy to Inhibit Coronary Atherosclerosis and Myocardial Injury in Patients With Necrotic High-Risk Coronary Plaque Disease), which is not on this map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Dual Antiplatelet Therapy to Inhibit Coronary Atherosclerosis and Myocardial Injury in Patients With Necrotic High-Risk Coronary Plaque Disease
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Pooled it
- CoronaryCirculation. Cardiovascular imaging · 2020Trial
- Article
- Temporal Changes in CoronaryJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Latent Coronary Plaque Morphology From Computed Tomography Angiography, Molecular Disease Activity on Positron Emission Tomography, and Clinical Outcomes.Arteriosclerosis, thrombosis, and vascular biology · 2023Article
- Thoracic AorticJACC. Cardiovascular imaging · 2022Observational
- Observer repeatability and interscan reproducibility of 18F-sodium fluoride coronary microcalcification activity.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Article
- Association of Lipoprotein(a) With Atherosclerotic Plaque Progression.Journal of the American College of Cardiology · 2022Article
- Machine Learning withJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Diagnosis, Investigation and Management of Patients with Acute and Chronic Myocardial Injury.Journal of clinical medicine · 2021Review
- Advances in Quantitative Analysis ofMolecular imaging · 2021Review
- Atherosclerosis Imaging withDiagnostics (Basel, Switzerland) · 2020Review
- Non-invasive imaging of high-risk coronary plaque: the role of computed tomography and positron emission tomography.The British journal of radiology · 2020Review
- An Update on [Journal of lipid and atherosclerosis · 2020Review
- Novel Positron Emission Tomography Tracers for Imaging Vascular Inflammation.Current cardiology reports · 2020Review
- CoronaryJournal of the American College of Cardiology · 2020Observational
- Atherosclerosis imaging withEuropean journal of nuclear medicine and molecular imaging · 2020Review
- Imaging Atherosclerosis by PET, With Emphasis on the Role of FDG and NaF as Potential Biomarkers for This Disorder.Frontiers in physiology · 2020Review
- Reproducibility of quantitative plaque measurement in advanced coronary artery disease.Journal of cardiovascular computed tomographyArticle
Corrections and comments
- Commented on by
Authors and funding
19 authors at 5 institutions in 2 countries.
Funding
Abstract
objectivesThe goal of this study was to determine whether ticagrelor reduces high-sensitivity troponin I concentrations in patients with established coronary artery disease and high-risk coronary plaque.
backgroundHigh-risk coronary atherosclerotic plaque is associated with higher plasma troponin concentrations suggesting ongoing myocardial injury that may be a target for dual antiplatelet therapy.
methodsIn a randomized, double-blind, placebo-controlled trial, patients with multivessel coronary artery disease underwent coronary
resultsIn total, 202 patients were randomized to treatment, and 191 met the pre-specified criteria for inclusion in the primary analysis. In patients with increased coronary
conclusionsDual antiplatelet therapy with ticagrelor did not reduce plasma troponin concentrations in patients with high-risk coronary plaque, suggesting that subclinical plaque thrombosis does not contribute to ongoing myocardial injury in this setting. (Dual Antiplatelet Therapy to Reduce Myocardial Injury [DIAMOND]; NCT02110303).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.